• FDA Rejects Gout Pain Drug Application

    by  • 10 November 2011 • Pain News

    Novartis was informed by the FDA that in order for the drug to be considered as a gout therapy in the future, further data in refractory patients will be needed. Although canakinumab showed efficacy in its clinical trials, specifically by reducing gout attacks and curbing pain, the FDA ultimately was troubled by what it believed to be an unacceptably high rate of serious infections (1.9%).


    After thirty years in the investment and public relations field, we have switched our focus lobbing between American and European companies facilitating business and licensing opportunities . Starting in the year 2003 L.G.Zangani, LLC has organized the annual event "Pharmafinance" in Milano and Roma. Pharmafinance is unique in its structure and has the ability to expose opportunities generated offering licensing or developing opportunities. Recently we have started the site www.letcombatpain.com creating the first worldwide site for pain news. The site also offers an humanitarian tools where individuals or professionals confronted by unique and rare forms of pain can communicate with all the members of the group simply sending oneemail. This ability of having a mass communication tool can also be used to expose innovative pain products or ideas. Additionally has also been invited as speaker to several conferences in Europe to discuss the uniqueness and functionality of his site .